Breast cancer and HSP90 inhibitors: is there a role beyond the HER2-positive subtype?

Breast. 2012 Aug;21(4):604-7. doi: 10.1016/j.breast.2012.04.002. Epub 2012 May 5.

Abstract

HSP90 inhibitors have shown great promise as therapeutic targets because they have the potential to suppress multiple signaling pathways simultaneously, and many are currently under clinical development. Because HER2 is known to be a client protein sensitive to inhibition of the HSP90 chaperone complex, HSP90 inhibitors have been studied in HER2-positive breast cancer and have shown promising results. In this article, we revisit HSP90 inhibitors in the context of breast cancer and discuss some notable preclinical data that reveal potential roles in both hormonal receptor-positive and triple negative breast tumor subtypes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Benzoquinones / therapeutic use
  • Biomarkers, Tumor / antagonists & inhibitors*
  • Biomarkers, Tumor / metabolism
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / metabolism
  • Female
  • HSP90 Heat-Shock Proteins / antagonists & inhibitors*
  • HSP90 Heat-Shock Proteins / metabolism
  • Humans
  • Lactams, Macrocyclic / therapeutic use
  • Receptor, ErbB-2 / metabolism

Substances

  • Antineoplastic Agents
  • Benzoquinones
  • Biomarkers, Tumor
  • HSP90 Heat-Shock Proteins
  • Lactams, Macrocyclic
  • 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin
  • tanespimycin
  • ERBB2 protein, human
  • Receptor, ErbB-2
  • geldanamycin